Difference between revisions of "Classical Hodgkin lymphoma - historical"
m |
Warner-admin (talk | contribs) m (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.'''" to "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.'''") |
||
Line 1: | Line 1: | ||
− | '''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].''' | + | '''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].''' |
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Hodgkin_lymphoma|main Hodgkin lymphoma page]] for current regimens. | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Hodgkin_lymphoma|main Hodgkin lymphoma page]] for current regimens. |
Revision as of 16:36, 11 December 2017
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main Hodgkin lymphoma page for current regimens.
30 regimens on this page
37 variants on this page
|
Guidelines
ESMO
- Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) PubMed
NCCN
Untreated
COPP
back to top |
COPP: CCNU (Lomustine), Oncovin (Vincristine), Procarbazine, Prednisone
Regimen
Study | Evidence | Comparator | Efficacy |
Cooper et al. 1980 | Phase III | CVPP | Seems not superior |
MOPP | Seems not superior | ||
MVPP | Seems not superior |
Chemotherapy
References
- Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. link to original article PubMed
CVPP
back to top |
CVPP: CCNU (Lomustine), Vinblastine, Procarbazine, Prednisone
Regimen
Study | Evidence | Comparator | Efficacy |
Cooper et al. 1980 | Phase III | COPP | Seems not superior |
MOPP | Seems to have superior CR rate | ||
MVPP | Seems not superior |
Chemotherapy
References
- Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. link to original article PubMed
MVPP
back to top |
MVPP: Mechlorethamine, Vinblastine, Procarbazine, Prednisone
Regimen
Study | Evidence | Comparator | Efficacy |
Cooper et al. 1980 | Phase III | COPP | Seems not superior |
CVPP | Seems not superior | ||
MOPP | Seems not superior |
Chemotherapy
References
- Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. link to original article PubMed
NOVP
back to top |
NOVP: Novantrone (Mitoxantrone), Oncovin (Vincristine), Vinblastine, Prednisone
Regimen
Study | Evidence |
Hagemeister et al. 1990 | Phase II |
Chemotherapy
References
- Hagemeister FB, Cabanillas F, Velásquez WS, Meistrich ML, Liang JC, McLaughlin P, Redman JR, Romaguera JE, Rodríguez MA, Swan F Jr, et al. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin Oncol. 1990 Dec;17(6 Suppl 10):34-8.PubMed
SCAB
back to top |
SCAB: Streptozocin, CCNU (Lomustine), Adriamycin (Doxorubicin), Bleomycin
Regimen
Study | Evidence |
Diggs et al. 1981 | Non-randomized |
Chemotherapy
References
- Diggs CH, Wiernik PH, Sutherland JC. Treatment of advanced untreated Hodgkin's disease with SCAB--an alternative to MOPP. Cancer. 1981 Jan 15;47(2):224-8. link to original article PubMed
- Update: Wiernik PH, Schiffer CA. Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB). J Cancer Res Clin Oncol. 1988;114(1):105-7. PubMed
Relapsed or refractory, salvage therapy
ABDIC
back to top |
ABDIC: Adriamycin (Doxorubicin), Bleomycin, DIC (Dacarbazine), CCNU (Lomustine), Prednisone
Regimen
Study | Evidence |
Rodgers et al. 1980 | Phase II |
Chemotherapy
- Doxorubicin (Adriamycin)
- Bleomycin (Blenoxane)
- Dacarbazine (DTIC)
- Lomustine (Ceenu)
- Prednisone (Sterapred)
References
- Rodgers RW, Gamble JF, Loh KK, Shullenberger CC. Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease. Cancer. 1980 Dec 1;46(11):2349-55. link to original article PubMed
- Update: Tannir N, Hagemeister F, Velasquez W, Cabanillas F. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol. 1983 Jul;1(7):432-9. link to original article PubMed
ABVD
back to top |
ABVD: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine
Regimen
Study | Evidence |
Krikorian et al. 1978 | Phase II |
Santoro et al. 1979 | Phase II |
Harker et al. 1984 | Non-randomized |
This is for historical interest only; ABVD is no longer used in the salvage setting.
Chemotherapy
References
- Krikorian JG, Portlock CS, Rosenberg SA. Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy. Cancer. 1978 Jun;41(6):2107-11. link to original article PubMed
- Santoro A, Bonadonna G. Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother Pharmacol. 1979;2(2):101-5. PubMed
- Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med. 1982 Feb;96(2):139-43. link to original article PubMed
- Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med. 1984 Oct;101(4):440-6. link to original article PubMed
B-CAVe
back to top |
B-CAVe: Bleomycin, CCNU (Lomustine), Adriamycin (Doxorubicin), Vinblastine
Regimen
Study | Evidence |
Porzig et al. 1978 | Non-randomized |
Harker et al. 1984 | Non-randomized |
Chemotherapy
References
- Porzig KJ, Portlock CS, Robertson A, Rosenberg SA. Treatment of advanced Hodgkin's disease with B-CAVE following MOPP failure. Cancer. 1978 May;41(5):1670-5. link to original article PubMed
- Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med. 1984 Oct;101(4):440-6. link to original article PubMed
BVCPP
back to top |
BVCPP: BCNU (Carmustine), Vinblastine, Cyclophosphamide, Procarbazine, Prednisone
Regimen
Study | Evidence |
Durant et al. 1978 | Non-randomized |
Chemotherapy
- Carmustine (BiCNU)
- Vinblastine (Velban)
- Cyclophosphamide (Cytoxan)
- Procarbazine (Matulane)
- Prednisone (Sterapred)
Patients who achieved CR were randomized to no additional therapy, 6 monthly cycles of MOPP or 6 additional monthly cycles of BVCPP.
References
- Durant JR, Gams RA, Velez-Garcia E, Bartolucci A, Wirtschafter D, Dorfman R. BCNU, velban, cyclophosphamide, procarbazine, and prednisone (BVCPP) in advanced Hodgkin's disease. Cancer. 1978 Nov;42(5):2101-10. link to original article PubMed
CEP
back to top |
CEP: CCNU (Lomustine), Etoposide, Prednimustine
Regimen
Study | Evidence |
Santoro et al. 1986 | Non-randomized |
Chemotherapy
References
- Santoro A, Viviani S, Valagussa P, Bonfante V, Bonadonna G. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol. 1986 Mar;13(1 Suppl 1):23-6. PubMed
SCAB
back to top |
SCAB: Streptozocin, CCNU (Lomustine), Adriamycin (Doxorubicin), Bleomycin
Regimen
Study | Evidence |
Levi et al. 1977 | Non-randomized, <20 pts |
Chemotherapy
References
- Levi JA, Wiernik PH, Diggs CH. Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozotocin, CCNU, adriamycin and bleomycin. Med Pediatr Oncol. 1977;3(1):33-40. PubMed